Non-canonical integrin signaling activates EGFR and RAS-MAPK-ERK signaling in small cell lung cancer
Karla Rubio, Addi J. Romero‐Olmedo, Pouya Sarvari, Guruprasadh Swaminathan, Vikas Ranvir, Diana G. Rogel-Ayala, Julio Cordero, Stefan Günther, Aditi Mehta, Birgit Bassaly, Peter Braubach, Małgorzata Wygrecka, Stefan Gattenlöhner, Achim Tresch, Thomas Braun, Gergana Dobreva, Miguel N. Rivera, Indrabahadur Singh, Johannes Graumann, Guillermo Barreto
Abstract
We uncovered a mechanism of ITGB2-mediated EGFR activation in SCLC that explains EGFR-inhibitor resistance independently of EGFR mutations, suggesting the development of therapies targeting ITGB2 for patients with this extremely aggressive lung cancer type.
Topics & Concepts
MAPK/ERK pathwayEpidermal growth factor receptorLung cancerCancer researchSignal transductionEpidermal growth factorBiologyIntegrinCell growthCellReceptorCell biologyMedicinePathologyGeneticsExtracellular vesicles in diseaseLung Cancer Research StudiesRNA modifications and cancer